December 6, 2000
JERUSALEM--(BUSINESS WIRE)--Dec. 5, 2000 via NewsEdge Corporation - Teva Pharmaceutical Industries, Ltd., (Nasdaq: TEVA) announced today that Copaxone(R)was launched in the U.K., the product's first major European market.
Copaxone(R) (glatiramer acetate for injection) is indicated for reduction in frequency of relapses in relapsing-remitting multiple sclerosis (RR-MS). There are approximately 85,000 patients in the U.K of which 30,000 are RR-MS patients.
Copaxone(R)will be jointly marketed in the U.K. by Teva and Aventis.
Peter Cardy, Chief Executive of the U.K. MS Society said: "The MS Society welcomes the availability of another therapy which can improve the quality of life for many people with MS."
Recent published results of a six-year follow-up trial with Copaxone(R) - the only organized MS therapeutic trial ever to be maintained for such a long duration in RR-MS patients - demonstrated a sustained clinical benefit and its safety profile.
Copaxone(R) has been approved for marketing in 19 countries including the U.S., Israel, Canada, Australia and Switzerland and has been used worldwide in over 30,000 patients. In the U.S., the major market of the product, Copaxone(R) is the fastest growing multiple sclerosis therapy, outpacing the overall MS drug market with a market share exceeding 25%.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 50 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of its sales are outside Israel, mainly in North America and Europe. The Company develops, manufactures and markets generic and branded pharmaceuticals and active pharmaceutical ingredients.
Safe Harbor Statement: This report contains forward-looking statements,
which express the beliefs and expectations of management. Such statements
are based on current expectations and involve a number of known and unknown
risks and uncertainties that could cause the Company's future results,
performance or achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward looking statements.
Important factors that could cause or contribute to such differences include
the impact of pharmaceutical industry regulation, the difficulty of predicting
FDA and other regulatory authority approvals, the regulatory environment
and changes in the health policies and structure of various countries,
acceptance and demand for new pharmaceutical products and new therapies,
the impact of competitive products and pricing, the availability and pricing
of ingredients used in the manufacture of pharmaceutical products, uncertainties
regarding market acceptance of innovative products newly launched, currently
being sold or in development, the impact of restructuring of clients, reliance
on strategic alliances, fluctuations in currency, exchange and interest
rates, operating results, the impact of the year 2000 issue and other factors
that are discussed in the Company's Annual Report on Form 20-F and the
Company's other filings with the U.S. Securities and Exchange Commission.
CONTACT: Teva Pharmaceutical Industries Ltd. | Dan Suesskind, Chief
Financial Officer | 011-972-2-589-2840 | or | Teva North-America. | Bill
Fletcher, President & CEO | 215/591-3000 | or | Teva Pharmaceutical
Industries Ltd. | Dorit Meltzer, Director, Investor Relations | 011-972-3-926-7554